Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) and Yarrow Bioscience (NASDAQ:YARW – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.
Profitability
This table compares Werewolf Therapeutics and Yarrow Bioscience’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Werewolf Therapeutics | N/A | -166.99% | -59.88% |
| Yarrow Bioscience | -4,726.21% | -84.40% | -77.68% |
Insider & Institutional Ownership
64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 83.8% of Yarrow Bioscience shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by insiders. Comparatively, 3.0% of Yarrow Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Volatility & Risk
Earnings and Valuation
This table compares Werewolf Therapeutics and Yarrow Bioscience”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Werewolf Therapeutics | $21.00 million | 2.28 | -$60.82 million | ($0.76) | -1.29 |
| Yarrow Bioscience | $570,000.00 | 122.45 | -$26.48 million | ($14.64) | -1.79 |
Yarrow Bioscience has lower revenue, but higher earnings than Werewolf Therapeutics. Yarrow Bioscience is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Werewolf Therapeutics and Yarrow Bioscience, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Werewolf Therapeutics | 1 | 4 | 2 | 0 | 2.14 |
| Yarrow Bioscience | 1 | 0 | 2 | 0 | 2.33 |
Werewolf Therapeutics presently has a consensus price target of $4.00, indicating a potential upside of 306.50%. Yarrow Bioscience has a consensus price target of $58.00, indicating a potential upside of 121.88%. Given Werewolf Therapeutics’ higher probable upside, equities research analysts plainly believe Werewolf Therapeutics is more favorable than Yarrow Bioscience.
Summary
Werewolf Therapeutics beats Yarrow Bioscience on 7 of the 13 factors compared between the two stocks.
About Werewolf Therapeutics
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
About Yarrow Bioscience
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
